MAIA Biotechnology, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by MAIA Biotechnology, Inc. on March 13, 2023, covering events occurring between March 13 and March 17, 2023. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Chicago, Illinois.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The primary material change reported is the restructuring of the Board of Directors:
- Resignation: Laurentiu Vlad resigned as a Class III Director and member of the Audit Committee effective March 16, 2023, citing personal reasons. The resignation did not involve any disagreement with the Company regarding operations, policies, or practices.
- Election: Jean-Manassé Theagène was elected as a Class III Director on March 17, 2023, to fill the vacancy left by Mr. Vlad. His term extends until the 2025 annual meeting of stockholders.
- Committee Appointment: Stan Smith was appointed to the Audit Committee on March 16, 2023, to replace Mr. Vlad.
Outlook, Risks, and Unusual Items
The filing notes that Mr. Theagène will participate in the Company's compensation program for independent directors as described in the Form S-1 filed on February 6, 2023. Additionally, the Company plans to enter into an indemnification agreement with Mr. Theagène, substantially identical to those held by other directors and officers, providing rights to indemnification and expense advancement under Delaware General Corporation Law. No other risks, contingencies, or unusual items were disclosed in this report.
Key Facts for Investor Verification
- Verify the effective dates of the director resignation (March 16, 2023) and election (March 17, 2023).
- Confirm that the resignation of Laurentiu Vlad was not related to any disagreement with the Company.
- Review the Form S-1 filed on February 6, 2023, for details on the director compensation program applicable to the new appointee.
- Note that the Audit Committee vacancy was filled immediately by the appointment of Stan Smith.